LEIDOS BIOMEDICAL RESEARCH INC: $342M Department of Health and Human Services Contract
Summary
Leidos Holdings ($LDOS) was awarded a $342M task order from the NIH for NCI operations, representing ~2.2% of annual revenue. The contract reinforces Leidos' position in health IT and government services, with moderate positive impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Leidos wins $342M NIH task order for NCI operations, adding ~2.2% to annual revenue.
- 2.Contract is a delivery order under existing IDIQ, indicating stable recurring business.
- 3.No direct legislative catalyst, but NIH funding is consistent with healthcare appropriations.
Market Implications
The contract is positive for LDOS, reinforcing its health segment revenue. However, given the company's $15.3B revenue base, the impact is moderate. Other health IT firms like $BAH or $ORCL may see indirect benefits if they are subcontractors, but no direct linkage is confirmed. The contract does not signal a sector-wide shift, but it underscores steady demand for health IT services from the NIH.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, awarded a $342M delivery order to Leidos Biomedical Research Inc. for the NCI Operational Task Order covering FY26-FY27. This is a single-year contract (August 2025 to August 2026) providing operational support to the National Cancer Institute. Leidos Holdings, Inc. ($LDOS) is the direct parent company, as confirmed by SEC filings. With FY2025 revenue of $15.3B, this contract adds about 2.24% to top-line revenue. However, Leidos' net margin is only 1.3%, so the net income contribution is roughly $4.4M, which is less than 2.2% of net income. The contract is a renewal or continuation of existing work, not a new market entry.
Leidos' health segment is a key differentiator, and this contract provides stable revenue visibility. The company has a strong track record with NIH and other federal health agencies. The contract is a delivery order, meaning it was issued under a previously awarded indefinite-delivery/indefinite-quantity (IDIQ) contract, reducing competitive risk. No related legislation appears to directly authorize this specific task order, but NIH funding is part of annual appropriations.
Supply chain beneficiaries are likely smaller IT and consulting firms that subcontract to Leidos. Common subcontractors in this space include Cerner (now part of Oracle Health, $ORCL) and Booz Allen Hamilton ($BAH), though neither is a direct subcontractor here. Pure-play health IT firms like Health Catalyst ($HCAT) or Evolent Health ($EVH) could benefit indirectly if they provide specialized services, but the connection is weak.
Historically, Leidos has seen steady revenue growth from NIH contracts, and the stock tends to react positively to large task order awards, though the magnitude of price movement is usually modest (1-3%) given the company's size and diversification. The contract does not shift competitive dynamics, but it reinforces Leidos' position as a top-tier health IT contractor.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award of a delivery order under an existing contract for operational support to the National Cancer Institute.
Who must act
National Institutes of Health (NIH) as the awarding agency; Leidos Biomedical Research Inc. as the recipient and prime contractor.
What happens
$342 million added to Leidos' backlog, representing approximately 2.24% of its FY2025 annual revenue of $15.3 billion.
Stock impact
This task order strengthens Leidos' health and life sciences segment, which is a core growth area. The low net margin (1.3%) means the net income impact is modest, but the contract reinforces long-term relationships with NIH and provides stable revenue.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Department of Homeland Security Appropriations Act, 2027
Slash the Pentagon Act
LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
FIT Procurement Act
VICTIM Act of 2026
YALI Act of 2025
U.S. Customs and Border Protection Officer Retirement Technical Corrections Act
To amend the Homeland Security Act of 2002 to direct the Secretary of Homeland Security, acting through the Commissioner of U.S. Customs and Border Protection, to implement large-scale, non-intrusive inspection technology at land ports of entry identified as high risk, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Adjusting Imports of Polysilicon and its Derivatives into the United States
This proclamation invokes Section 232 of the Trade Expansion Act to impose a minimum import price (MIP) program on polysilicon and its derivatives, a 15% ad valorem tariff on polysilicon derivatives, and directs the Secretary of Commerce to offer incentives for domestic production. It aims to protect and revive the U.S. polysilicon industry by restricting imports that threaten national security, particularly for semiconductor and solar supply chains.
Contract Details
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$342,250,840
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →